If you are searching whether psilocybin slows aging, the direct answer is that as of November 2026, the lifespan study cited here is a 2025 lab and mouse study from Emory University; it tested cells and mice, not people. The human research that connects age to psilocybin looks at depression, where older age was linked to larger symptom improvements.
Why psilocybin and age are in the news
Searches about psilocybin and age draw on two kinds of research: aging studies and depression studies. Most of the confusion comes from mixing two different questions:
- Does psilocybin affect aging itself, such as cell lifespan or survival?
- Does a person’s age change how well psilocybin works for depression?
Does psilocybin slow aging or extend lifespan?
The main study is the 2025 npj Aging paper “Psilocybin treatment extends cellular lifespan and improves survival of aged mice,” by researchers at Emory University. Its authors call psilocybin a possible “geroprotective agent” and say more studies are needed. The study used psilocybin and psilocin obtained from a chemical supplier, not whole mushrooms, and it tested cells and mice, not people.
| Part of the study | What it found |
|---|---|
| Human cells grown in a dish (lung and adult skin fibroblasts) | Psilocin, the active metabolite of psilocybin, extended cell lifespan by 29% at 10 µM and 57% at 100 µM in lung cells, and by 51% at 100 µM in adult skin cells. |
| Aged female mice (19 months old at start) | Survival was 80% (24 of 30) with psilocybin and 50% (14 of 28) with vehicle, after 10 monthly treatments. |
Read these cell and mouse results as early context, not as proof for people. The authors note that the cell results showed no evidence of cancer-causing change, but they say long-term effects on cancer risk need study. The mice were not blinded to their group, and only female mice were used.
What is the psilocybin-telomere hypothesis?
The paper describes telomere length as a hallmark of cellular aging. The psilocybin-telomere hypothesis proposes that psilocybin may quantifiably affect telomere length, which could help explain its effects across several conditions. In the cell experiments, telomere length was preserved in psilocin-treated cells, while vehicle-treated cells that had aged showed shorter telomeres. The authors say their work supports the hypothesis; it is not a settled finding.
Does age change how psilocybin works for depression?
This is the age question with human data behind it. The 2024 BMJ meta-analysis pooled 436 participants from seven trials and found psilocybin improved depression scores compared with comparison treatments. Its exploratory analysis linked older age and previous psychedelic use to larger improvements. The authors rate the overall certainty of evidence as moderate and call for more research on expectancy effects. For why trials need a placebo group, see why trials need a placebo group (our research library).
| Study | Who took part | What it found | Limits |
|---|---|---|---|
| 2021 JAMA Psychiatry trial | 27 randomized adults with major depressive disorder; 24 completed; waitlist control group | Two sessions (20 mg/70 kg, then 30 mg/70 kg) with about 11 hours of supportive psychotherapy. At week 4, depression scores in the immediate group averaged 8.5, versus 23.5 in the delayed group at week 8. | Small trial; 67% of participants were women |
| 2024 BMJ meta-analysis | 436 participants in seven trials, average age 36 to 60 | Psilocybin beat comparators for depression (Hedges g 0.66). Older age and previous psychedelic use were linked to bigger improvements. | Moderate risk of bias; moderate certainty of evidence |
| 2025 npj Aging study (npj Aging paper) | Human cells in a dish; 19-month-old female mice | Cell lifespan extended by 29% to 57% in lung cells; higher mouse survival with psilocybin | Lab and mouse only; not blinded; female mice only |
Psilocybin benefits and risks: what are the side effects?
The 2024 JAMA Network Open review pooled six randomized, double-blind trials with 528 people treated for depression or anxiety. It found several side effects were more common with psilocybin than with comparison groups. The authors say these were tolerable and resolved within 48 hours, and they call for better study of how to manage them.
| Side effect | Relative risk (95% CI) |
|---|---|
| Nausea | 8.85 (5.68 to 13.79) |
| Dizziness | 5.81 (1.02 to 33.03) |
| Anxiety | 2.27 (1.11 to 4.64) |
| Elevated blood pressure | 2.29 (1.15 to 4.53) |
| Headache | 1.99 (1.06 to 3.74) |
A relative risk above 1 means the side effect happened more often in the psilocybin group. Paranoia and transient thought disorder were not linked to psilocybin use in this review. These figures describe the hours and days after a dose, not years of use.
Does psilocybin have long-term effects or cause permanent brain damage?
The Emory paper cites earlier human studies reporting that a single dose of psilocybin had “durable effects (up to ~5 years)” on symptoms. That is the paper’s summary of earlier trials, not a new finding. The 2021 trial followed participants to week 8, so the studies on this page cannot settle whether there is permanent brain harm. For lasting effects and brain research, read our Psilocybin long-term effects guide and Psilocybin brain effects guide.
Is 25 mg of psilocybin a microdose, and is 1 gram a lot?
Psilocybin doses in research are measured in milligrams. The Emory paper describes 25 mg as a “psychedelic dose” used in a chronic pain study, and the 2021 depression trial gave 20 mg per 70 kg of body weight, then 30 mg per 70 kg. None of the studies on this page tested microdosing, so they cannot tell you whether a small amount helps.
No study on this page gives a figure for what 1 gram of a mushroom product contains, so do not assume a gram is a research-sized dose. Check the amount on the product label, and ask a clinician what any amount would mean for you, because the NCCIH notes that what is on a supplement label may not match what is in the product.
Psilocybin skin benefits and anti-aging doses
None of the studies here tested psilocybin on skin in people. The only skin-related observation is in the mouse study, where the authors saw fur changes, including hair growth and fewer white hairs, but did not measure them quantitatively. For skin care, a dermatologist is the right person to ask.
There is no human anti-aging dose in this research. The mice received a lower dose first and then a higher monthly dose, in a lab setting. Do not convert those amounts into a human dose. A clinician can talk through any dosing question with you.
Is psilocybin legal and approved for treatment?
The 2025 Emory paper describes psilocybin as a Schedule I controlled substance in the US. Check current legal status with the relevant US agency before you act on it. The 2021 Molecules review says the US government rescheduled psychedelics as Schedule 1 drugs in 1970, and that this prohibition significantly delayed advances in medical knowledge about psilocybin. The Emory paper refers to a special FDA expedited-review designation for psilocybin. That is not an approval, so check the FDA website for current status. Our Compass Pathways FDA status guide covers the phase 3 trials. This is information, not legal advice.
What are the other routes people try for healthy aging?
Mushroom products sold as dietary supplements fall under rules that are less strict than those for drugs. The NCCIH says the FDA is not authorized to review most dietary supplements for safety and effectiveness before they are marketed. It also says supplements may interact with medications or pose risks with certain medical conditions or surgery.
| Option | Status | What the research says | Main limit |
|---|---|---|---|
| Psilocybin in depression trials | Clinical research | Trials show benefit for depression compared with comparators, as above | Small trials; expectancy effects still need study |
| Psilocybin for aging | Lab and mouse research only | Longer cell lifespan and higher mouse survival in the 2025 study | No human aging data yet |
| Multivitamins | Everyday dietary supplement | The NCCIH guide says most research shows multivitamins do not result in living longer or slowing cognitive decline | Unlikely to pose health risks, per the NCCIH |
| Reishi mushroom | Dietary supplement with traditional use | The NCI summary says reishi was thought in East Asian tradition to prolong life and prevent aging; the FDA has not approved it for any medical condition | Can raise bleeding risk with blood thinners, per the MSK reishi summary |
Costs vary and change, so check today’s price directly with the seller or your clinic.
Questions to take to a clinician
If you are considering psilocybin, a supplement or a clinical study, bring these questions to a clinician or pharmacist:
- Given my health history and medications, is psilocybin something I should discuss at all?
- What amount does this product contain, and how can I confirm it?
- Which side effects in the table above would matter most for me?
- Are there trials I could join, and what would taking part involve?
The age question in human research is about mood, while the aging question is still in lab and animal work. Start with your clinician, then return to the research above to ask better questions.
By MushroomHealthBenefits.com Research & Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.